Rubius Therapeutics Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rubius Therapeutics in the last twelve months. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Rubius Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RUBY, but not buy additional shares or sell existing shares.
View analyst ratings for Rubius Therapeutics or view top-rated stocks.

Wall Street analysts have given Rubius Therapeutics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Rubius Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Rubius Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Rubius Therapeutics.

Rubius Therapeutics, Inc. (NASDAQ:RUBY) announced its quarterly earnings results on Monday, May, 10th. The company reported ($0.51) EPS for the quarter, topping analysts' consensus estimates of ($0.54) by $0.03.
View Rubius Therapeutics' earnings history.

Rubius Therapeutics' stock was trading at $6.55 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RUBY stock has increased by 321.4% and is now trading at $27.60.
View which stocks have been most impacted by COVID-19.

4 Wall Street analysts have issued 12 month price objectives for Rubius Therapeutics' shares. Their forecasts range from $20.00 to $40.00. On average, they anticipate Rubius Therapeutics' share price to reach $28.33 in the next year. This suggests a possible upside of 2.7% from the stock's current price.
View analysts' price targets for Rubius Therapeutics or view top-rated stocks among Wall Street analysts.

12 employees have rated Rubius Therapeutics CEO Pablo Cagnoni on Glassdoor.com. Pablo Cagnoni has an approval rating of 91% among Rubius Therapeutics' employees. This puts Pablo Cagnoni in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Rubius Therapeutics include CRISPR Therapeutics (CRSP), Neurocrine Biosciences (NBIX), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Acceleron Pharma (XLRN), Exelixis (EXEL), Halozyme Therapeutics (HALO), Vir Biotechnology (VIR), Twist Bioscience (TWST), Beam Therapeutics (BEAM), Adaptive Biotechnologies (ADPT), Recursion Pharmaceuticals (RXRX), Sana Biotechnology (SANA), Kodiak Sciences (KOD) and Abcam (ABCM).
View all of RUBY's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Rubius Therapeutics investors own include Sorrento Therapeutics (SRNE), Marinus Pharmaceuticals (MRNS), Xeris Pharmaceuticals (XERS), Fulcrum Therapeutics (FULC), Recro Pharma (REPH), TG Therapeutics (TGTX), Tilray (TLRY), Viking Therapeutics (VKTX), ADMA Biologics (ADMA) and Adverum Biotechnologies (ADVM).

(RUBY) raised $200 million in an initial public offering (IPO) on Wednesday, July 18th 2018. The company issued 9,500,000 shares at a price of $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners served as the underwriters for the IPO.

Rubius Therapeutics trades on the NASDAQ under the ticker symbol "RUBY."

Rubius Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Flagship Pioneering Inc. (43.11%), Baillie Gifford & Co. (5.78%), BlackRock Inc. (4.48%), JPMorgan Chase & Co. (2.79%), Federated Hermes Inc. (1.63%) and Victory Capital Management Inc. (1.48%). Company insiders that own Rubius Therapeutics stock include Christina M Coughlin, Christopher L Carpenter, David R Epstein, Maiken Keson-Brookes, Pablo J Cagnoni, Robert Langer and Ventures Fund Iv Gene Flagship.
View institutional ownership trends for Rubius Therapeutics.

RUBY stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Caas Capital Management LP, Renaissance Technologies LLC, Ameriprise Financial Inc., Russell Investments Group Ltd., Millennium Management LLC, Nuveen Asset Management LLC, and Alliancebernstein L.P.. Company insiders that have sold Rubius Therapeutics company stock in the last year include David R Epstein, and Maiken Keson-Brookes.
View insider buying and selling activity for Rubius Therapeutics or view top insider-selling stocks.

RUBY stock was bought by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Federated Hermes Inc., Deerfield Management Company L.P. Series C, BlackRock Inc., State of Michigan Retirement System, Voloridge Investment Management LLC, Flagship Pioneering Inc., and Compagnie Lombard Odier SCmA. Company insiders that have bought Rubius Therapeutics stock in the last two years include Christina M Coughlin, David R Epstein, Pablo J Cagnoni, and Ventures Fund Iv Gene Flagship.
View insider buying and selling activity for Rubius Therapeutics or or view top insider-buying stocks.

Shares of RUBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RUBY stock can currently be purchased for approximately $27.60.

Rubius Therapeutics has a market capitalization of $2.47 billion. The company earns $-167,730,000.00 in net income (profit) each year or ($2.08) on an earnings per share basis.

Rubius Therapeutics employs 204 workers across the globe.

The official website for Rubius Therapeutics is www.rubiustx.com.

Rubius Therapeutics is headquartered at 399 BINNEY STREET SUITE 300, CAMBRIDGE MA, 02139.

Rubius Therapeutics' mailing address is 399 BINNEY STREET SUITE 300, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-679-9600 or via email at [email protected]